Karen Lasch Selected Research

vedolizumab

7/2023	Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
1/2022	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
1/2022	Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
6/2021	Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
12/2020	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
7/2020	Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs.
6/2020	Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
1/2020	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
1/2020	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
11/2019	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karen Lasch Research Topics

Disease

18	Ulcerative Colitis 07/2023 - 01/2017
15	Crohn Disease (Crohn's Disease) 07/2023 - 01/2017
7	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2019 - 01/2017
6	Infections 01/2022 - 01/2017
3	Necrosis 06/2020 - 01/2019
1	Inflammation (Inflammations) 01/2023
1	Ulcer 01/2020
1	Abdominal Pain (Pain, Abdominal) 01/2019
1	Hemorrhage 01/2019
1	Fistula 04/2018
1	Lymphoma (Lymphomas) 01/2018

Drug/Important Bio-Agent (IBA)

23	vedolizumabIBA 07/2023 - 01/2017
5	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 01/2017
4	IntegrinsIBA 07/2023 - 01/2017
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2023 - 01/2019
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 11/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 04/2018
2	Monoclonal AntibodiesIBA 01/2019 - 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	tofacitinibIBA 06/2021
1	Azathioprine (Imuran)FDA LinkGeneric 06/2020
1	Antiviral Agents (Antivirals)IBA 01/2020
1	SteroidsIBA 01/2020
1	Serum AlbuminIBA 01/2019
1	C-Reactive ProteinIBA 10/2018
1	acceleratory factor from growth hormone (AcG)IBA 07/2017

Therapy/Procedure

13	Therapeutics 07/2023 - 01/2017
3	Colectomy 01/2023 - 01/2018
2	Biological Therapy 01/2018 - 01/2017
1	Immunotherapy 10/2019